ENDPOINTS

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug

7 years ago

News Briefing

FDA stiff-arms Aveo on tivo, again; Sunovion Parkinson's drug rejected

7 years ago

News Briefing

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data

7 years ago

News Briefing

Rituxan copycat passes first pivotal test for Amgen, Allergan; Ironwood and biotech spinout name new boards

7 years ago

News Briefing

RNAi leader Alnylam inks collaboration pact with startup; GV's Rosana Kapeller joins Schrödinger board

7 years ago

News Briefing

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

7 years ago

Special

Pharma

Tossed in a storm of controversies, Proteostasis finds shelter in $100M cash Roche deal — shares surge

7 years ago

Pharma

European VC firm Kurma sets its sights on €150 million fund, its biggest ever

7 years ago

Financing

Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline

7 years ago

R&D

Pharma

Under pressure, drugmakers dilute price hikes, but nothing is set in stone just yet — report

7 years ago

Pharma

Mylan claims win in Lantus patent battle, but legal war with Sanofi is far from over

7 years ago

Pharma

Lilly, Incyte's baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

7 years ago

News Briefing

Third Rock, Takeda-backed Ambys ushers in ex-NGM Bio president Jeff Jonker as CEO

7 years ago

People

'Idea Man' Paul Allen leaves behind plan to unscramble human immunology

7 years ago

People

Art Krieg moves from CEO post to CSO at Checkmate; Indivior breathes sigh of relief after court ruling

7 years ago

News Briefing

Mallinckrodt's woes persist as reformulated opioid painkiller fails to pass FDA muster

7 years ago

R&D

Bausch is keen on Synergy, after troubled constipation drug maker files for Chapter 11

7 years ago

Pharma

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

7 years ago

News Briefing

Large coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare

7 years ago

Pharma

Targeting CD47? UCLA joins bandwagon, with gel to stem tumors from resurfacing

7 years ago

Discovery

Shanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data

7 years ago

News Briefing

AstraZeneca, Cancer Research UK set up genomics hub to fight uphill battle against cancer

7 years ago

R&D

Discovery

Sanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset

7 years ago

News Briefing

Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer

7 years ago

Pharma

about the author

author articles

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug

FDA stiff-arms Aveo on tivo, again; Sunovion Parkinson's drug rejected

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data

Rituxan copycat passes first pivotal test for Amgen, Allergan; Ironwood and biotech spinout name new boards

RNAi leader Alnylam inks collaboration pact with startup; GV's Rosana Kapeller joins Schrödinger board

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

Tossed in a storm of controversies, Proteostasis finds shelter in $100M cash Roche deal — shares surge

European VC firm Kurma sets its sights on €150 million fund, its biggest ever

Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline

Under pressure, drugmakers dilute price hikes, but nothing is set in stone just yet — report

Mylan claims win in Lantus patent battle, but legal war with Sanofi is far from over

Lilly, Incyte's baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

Third Rock, Takeda-backed Ambys ushers in ex-NGM Bio president Jeff Jonker as CEO

'Idea Man' Paul Allen leaves behind plan to unscramble human immunology

Art Krieg moves from CEO post to CSO at Checkmate; Indivior breathes sigh of relief after court ruling

Mallinckrodt's woes persist as reformulated opioid painkiller fails to pass FDA muster

Bausch is keen on Synergy, after troubled constipation drug maker files for Chapter 11

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

Large coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare

Targeting CD47? UCLA joins bandwagon, with gel to stem tumors from resurfacing

Shanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data

AstraZeneca, Cancer Research UK set up genomics hub to fight uphill battle against cancer

Sanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset

Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer